LAB Q4 2024 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q4 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$47M+65.7% YoY

Gross Profit

$22M46.9% margin

Operating Income

-$33M-70.2% margin

Net Income

-$34M-72.9% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+3.9%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$17M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$612M

Total Liabilities

$141M

Stockholders' Equity

$472M

Cash & Equivalents

$167M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$28M	+65.7%
Gross Profit	$22M	$13M	+64.0%
Operating Income	-$33M	-$21M	-53.5%
Net Income	-$34M	-$20M	-72.3%

Revenue Segments

Product And Service

$81M37%

Product

$45M21%

Service

$36M16%

Consumables

$36M16%

Instruments

$18M8%

Collaboration and Other Revenue

$3M1%

Geographic Segments

Americas

$45M54%

EMEA

$24M28%

Asia Pacific

$15M18%